$8.17
0.12% day before yesterday
Nasdaq, Jan 02, 10:04 pm CET
ISIN
US68622P1093
Symbol
ORIC

ORIC Pharmaceuticals Inc Stock price

$8.17
-2.48 23.29% 1M
-2.48 23.29% 6M
-0.01 0.12% YTD
-0.09 1.09% 1Y
+2.28 38.71% 3Y
-25.16 75.49% 5Y
-17.60 68.30% 10Y
-17.60 68.30% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.01 0.12%
ISIN
US68622P1093
Symbol
ORIC
Industry

Key metrics

Basic
Market capitalization
$795.7m
Enterprise Value
$508.5m
Net debt
positive
Cash
$287.1m
Shares outstanding
97.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.0
Financial Health
Equity Ratio
88.7%
Return on Equity
-52.6%
ROCE
-36.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-146.8m | $-147.1m
EBIT
$-148.0m | $-149.7m
Net Income
$-135.3m | $-154.4m
Free Cash Flow
$-116.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-10.1% | -3.8%
EBIT
-10.1% | -4.8%
Net Income
-12.4% | -20.7%
Free Cash Flow
-5.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.4
FCF per Share
$-1.2
Short interest
18.7%
Employees
115
Rev per Employee
$0.0
Show more

Is ORIC Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

ORIC Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a ORIC Pharmaceuticals Inc forecast:

18x Buy
90%
2x Hold
10%

Analyst Opinions

20 Analysts have issued a ORIC Pharmaceuticals Inc forecast:

Buy
90%
Hold
10%

Financial data from ORIC Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 32 32
14% 14%
-
- Research and Development Expense 116 116
9% 9%
-
-147 -147
10% 10%
-
- Depreciation and Amortization 1.21 1.21
14% 14%
-
EBIT (Operating Income) EBIT -148 -148
10% 10%
-
Net Profit -135 -135
12% 12%
-

In millions USD.

Don't miss a Thing! We will send you all news about ORIC Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ORIC Pharmaceuticals Inc Stock News

Neutral
Seeking Alpha
28 days ago
ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Results and Differentiation in EGFR-Mutated Non-Small Cell Lung Cancer Transcript
Neutral
GlobeNewsWire
29 days ago
Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases
Neutral
GlobeNewsWire
29 days ago
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on December 1, 2025 (the “Grant Date”), ORIC granted a total of 69,200 non-qualified stock options and 11,400 restricted stock units to thr...
More ORIC Pharmaceuticals Inc News

Company Profile

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.

Head office United States
CEO Jacob Chacko
Employees 115
Founded 2014
Website oricpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today